anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: Desquamative gingivitis (DG) is a clinical term indicating "peeling gums" and is associated with different oral manifestations. In this study, we aimed to assess the association between DG and autoimmune blistering mucocutaneous diseases (ABMD) with oral manifestations. Materials and Methods: A retrospective study including 88 patients diagnosed between 1998 and 2019 with ABMD (intraepithelial and subepithelial autoimmune blistering diseases) was performed at the Oral Medicine Department, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy in Bucharest. For each patient, the sociodemographic and anamnestic data, as well as clinical features of oral lesions (location), histological evaluation, and direct immunofluorescence data were collected. Results: Most of the patients involved in the study were female (78.4%). In total, 34 patients (38.63%) were diagnosed with subepithelial autoimmune diseases (SAD) and 54 (61.36%) had intraepithelial autoimmune diseases (IAD). Differences in the anatomic distribution of oral involvement were found between SAD and IAD. The presence of DG was significantly more common in patients with SAD compared to those with a diagnosis of IAD. Conclusions: Specific anatomical locations of the oral lesions are significantly associated with different subtypes of ABMD, with gingiva and hard palate mucosa being more involved in SAD and the soft palate and buccal mucosa in IAD. Desquamative gingivitis is a clinical sign that raises diagnostic challenges for several conditions in oral medicine.
Two pastilles (100 mg) taken three times a day (i.e. before meal time).
BACKGROUND AND PURPOSE: Logopenic variant primary progressive aphasia (lvPPA) is a major variant presentation of Alzheimer's disease (AD) that signals the importance of communication dysfunction across AD phenotypes. A clinical staging system is lacking for the evolution of AD-associated communication difficulties that could guide diagnosis and care planning. Our aim was to create a symptom-based staging scheme for lvPPA, identifying functional milestones relevant to the broader AD spectrum.
METHODS: An international lvPPA caregiver cohort was surveyed on symptom development under an 'exploratory' survey (34 UK caregivers). Feedback from this survey informed the development of a 'consolidation' survey (27 UK, 10 Australian caregivers) in which caregivers were presented with six provisional clinical stages and feedback was analysed using a mixed-methods approach.
RESULTS: Six clinical stages were endorsed. Early symptoms included word-finding difficulty, with loss of message comprehension and speech intelligibility signalling later-stage progression. Additionally, problems with hearing in noise, memory and route-finding were prominent early non-verbal symptoms. 'Milestone' symptoms were identified that anticipate daily-life functional transitions and care needs.
CONCLUSIONS: This work introduces a new symptom-based staging scheme for lvPPA, and highlights milestone symptoms that could inform future clinical scales for anticipating and managing communication dysfunction across the AD spectrum.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with ZIPSOR has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including ZIPSOR, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplateletagents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].
Novel preclinical research evidence suggests extinction learning as the core mechanism of action of exposure-based therapies and provides according strategies to improve the effectiveness of treatment by optimized extinction. A translational research agenda is suggested to examine whether enhanced extinction learning components derived from preclinical research, applied within an "intensified" exposure-based treatment, improves outcomes. In a multicenter randomized clinical trial, linked to mechanistic subprojects, the investigators test in n=620 patients with primary AD allowing for comorbidity whether intensified psychological interventions based on augmented extinction learning (IPI) result in faster, stronger and more persistent outcomes on subjective, clinical, behavioral, physiological and neural indices as compared to an, otherwise identical, standard research treatment without explicit enhanced extinction (TAU). The investigators hypothesize that (a) enhanced extinction elements (IPI) will result in higher effect sizes, faster recovery, (b) more pronounced changes in an array of systems, including elements of extinction learning and in objective behavioral measures assessed in intersession exposure trials. The investigators also examine moderators of outcome (i.e. type of diagnosis, comorbidity) and explore whether IPI is associated with lower health care costs.
PROBLEM TO BE SOLVED: To obtain a new compound having a new molecular skeleton and exhibiting antirheumatic activity. SOLUTION: The antibiotic substances epoxyquinomicin C and D are expressed by the formula (R is H for epoxyquinomicin C and C1 for epoxyquinomicin D). The epoxyquinomicin C has the following physical and chemical properties; appearance and nature, white powder having weakly acidic nature; melting point, 168-172 deg.C (decomposition); specific rotation, [α]D<25> =+128 deg. (c=1.0, methanol); etc. The compound of the formula can be produced by culturing a microbial strain capable of producing epoxyquinomicin C and D such as Amycolatopsis sp. MK299-95F4 in a nutrient medium at pH6.5-7.5 under aerobic condition.
Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
AIM: To investigate surgical treatment, postoperative rehabilitation and prevention of heterotopic ossification (HO) in patients with post-traumatic elbow stiffness.
METHODS: We performed a retrospective review of patients with post-traumatic elbow stiffness combined with HO between 2007 and 2021. This study was performed on a total of 15 patients (18 elbows) admitted to our hospital, consisting of 12 males and 3 females, with post-traumatic stiffness of the elbow combined with HO, where elbow function could not be recovered by rehabilitation and orthosis treatment. Fifteen patients were treated by surgical excision of heterotopic bones and release of elbow contracture combined with postoperative rehabilitation and orthosis-wearing. Comprehensive treatments, including radiation, oral ibuprofen medication, and manipulation techniques to improve range of motion, were used to prevent HO recurrence. The flexion-extension arc and functional score of the elbow were measured after treatment and compared with the preoperative measurements. Roentgenography was used to observe HO recurrence.
RESULTS: After surgical treatment and postoperative rehabilitation, the patients' range of motion improved, and the functional score improved considerably. The postoperative flexion-extension arc and The Hospital for Special Surgery (HSS) functional score were statistically significantly higher than the preoperative values (p < 0.01). Roentgenographic examination showed no HO recurrence during the follow-up period.
CONCLUSION: Surgical excision of heterotopic bones and elbow contracture release combined with postoperative rehabilitation and preventative HO measures can be an effective treatment for cases of post-traumatic elbow stiffness combined with HO, for which conservative treatment is ineffective.
Antibiotics pre-treatment on days 1-5 and a bowel cleansing on day 6. Days 7-14 are dedicated to active eradication treatment with FMT. First dose on day 7 and second dose in days 9-14 (1/6 of full dose every day).
This randomized controlled trial will be conducted with 420 drug-involved Black women at 5 probation sites located in communities in NYC heavily affected by HIV and STIs. Eligible women will be randomly assigned to: (1) WORTH consisting of an individual evidence-based Streamlined HIV Testing session followed by a 4-session group-based multimedia HIV intervention (WORTH) or (2) an individual Streamlined HIV Testing session alone (Streamlined HIV Testing), which will serve as the comparison condition. Both conditions will be delivered by Fortune providers at the 5 sites. Self-reported data on behavioral outcomes will be collected from participants via audio computer-assisted self-interview (ACASI). Primary STI outcomes will be measured via biological assay for infection by Neisseria gonorrhea, trichomonas, and Chlamydia trachomatis, the most common STIs found among women in NYC. Women who meet eligibility criteria will undergo a pre-intervention assessment. This assessment will last approximately 60 minutes, consisting of demographic information, history of criminal justice involvement, drug and alcohol use and dependence, sexual and drug-related HIV behaviors, HIV treatment and care, intimate partner violence, depression and posttraumatic Stress Disorder (PTSD) , service utilization, and social support. Research assistants (RAs) will schedule repeated assessments with participants that will take place at baseline and at 3, 6, and 12 months post-intervention. Each participant will be asked to obtain one vaginal specimen for STI testing by inserting a sterile Dacron-tipped swab about 2.5 inches or as far as comfortable into the vagina, rotating it for 15 to 30 seconds, and removing it. The vaginal swabs are placed into separate specimen transport packaging.
Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
The invention relates to the construction and the application of dual shRNA expression plasmid of dual chU6 promoter, belonging to the field of biopharmaceuticals. A chick U6 promoter (chU6) is built, and two small hairpin RNAs (shRNA) of which the target respectively aims at an IBDVVP1 gene and a VP2 gene, i.e. a VP1-shRNA2550 and VP2-shRNA392. An expression plasmid pSilencer2.1+2chU6+VP1VP2shRNA is built; chick embryo fibroblast (CEF) is transfected, IBDV (Infectious Bursal Disease Virus) is inoculated, and virus can be prevented from copying. The expression plasmid pSilencer2.1+2chU6+VP1VP2shRNA is mixed with IBDV; and the mixture is inoculated to a 10-day SPF (Specific pathogen Free) chick embryo allantoic cavity to prevent the chick embryo cavity from being suffered from IBDV infection. The dual shRNA expression plasmid of dual chU6 promoter, which is built by the invention, is a novel IBDV prevention preparation and has the advantages of good practical value and popularizing prospect.
<P>PROBLEM TO BE SOLVED: To effectively utilize electronic information showing medical information inputted in handwriting.  <P>SOLUTION: In this medical information processing system, an electronic pen acquires medical information data handwritten in an input area of a form. An attribute information extracting part 130 extracts attribute information specifying a state in which the medical information data is inputted by handwriting from the acquired medical information data. A processing determining part 150 determines processing to be executed to the medical information data from the extracted attribute information. A processing executing part 160 executes the determined processing. A storing part 110 stores prescribed attribute information while associating the prescribed attribute information with the processing to be executed to the medical information data. The processing determining part 150 determines to execute the processing stored in association with the prescribed attribute information to the medical information data.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: Primary congenital glaucoma (PCG) affects approximately 1 in 10,000 live born infants in the United States (U.S.). PCG has a autosomal recessive inheritance pattern, and variable expressivity and reduced penetrance have been reported. Likely causal variants in the most commonly mutated gene, CYP1B1, are less prevalent in the U.S., suggesting that alternative genes may contribute to the condition. This study utilized exome sequencing to investigate the genetic architecture of PCG in the U.S. and to identify novel genes and variants.
METHODS: We studied 37 family trios where infants had PCG and were part of the National Birth Defects Prevention Study (births 1997-2011), a U.S. multicenter study of birth defects. Samples underwent exome sequencing and sequence reads were aligned to the human reference sample (NCBI build 37/hg19). Variant filtration was conducted under de novo and Mendelian inheritance models using GEMINI.
RESULTS: Among candidate variants, CYP1B1 was most represented (five trios, 13.5%). Twelve probands (32%) had potentially pathogenic variants in other genes not previously linked to PCG but important in eye development and/or to underlie Mendelian conditions with potential phenotypic overlap (e.g., CRYBB2, RXRA, GLI2).
CONCLUSION: Variation in the genes identified in this population-based study may help to further explain the genetics of PCG.
PROBLEM TO BE SOLVED: To prepare a granule useful for a hygroscopic and water-soluble product, especially for a medicine or a treating agent, etc., for cultivated plants by carrying out the fluidized bed granulation while controlling the granule humidity of the product. SOLUTION: This hygroscopic and water-soluble product granule 1 having 200-2,000μm average grain diameter is prepared by bonding each of plural particle 2 having 5-200μm average particle diameter with solid bridges 3 of a solidified hygroscopic product and coating the surface of each particle 2 with the solid bridges 3. That is, each particle 2 becomes an aggregate coated with a hygroscopic product (e.g. sodium bentazon as an agrochemical). The resultant granule 1 has a compact and nearly spherical shape and further a cavity 4 and pore spaces 5 capable of manifesting capillary actions. Furthermore, the granule 1 is prepared by heating an aqueous solution containing 20-70wt.% hygroscopic and water-soluble product, spraying the heated solution on a fluidized bed opposite to the flow of a fluidizing gas and carrying out the fluidized bed granulation.  The product moisture in the granule 1 is regulated so as not to be >=50% based on the residual moisture in the final product granule 1.
The right ventricle plays an important role in the morbidity and mortality of patients presenting with signs and symptoms of cardiopulmonary disease. However, the systematic assessment of right heart function is not uniformly carried out. This is due partly to the enormous attention given to the evaluation of the left heart, a lack of familiarity with ultrasound techniques that can be used in imaging the right heart, and a paucity of ultrasound studies providing normal reference values of right heart size and function. In patients with CHD, the right ventricle (RV) may function as either the sub-pulmonary or the systemic ventricle as in transposition of great arteries (TGA). CHD more commonly affecting the right heart includes atrial septal defects (ASD), Tetralogy of Fallot (TOF), pulmonary stenosis (PS), Ebstein anomaly, arrhythmogenic right ventricular cardiomyopathy (ARVC), and pulmonary valve atresia. In many of these patients, prevention of "irreversible" right heart failure (RHF) will require timely corrective surgery or when not possible, surgical palliation . Congenital pulmonary valve stenosis is a common congenital heart disease. Isolated pulmonary valve stenosis comprises 8-10% of all congenital heart disease . While surgical pulmonary valvotomy has been available as a treatment since 1956, it requires a median sternotomy, use of cardiopulmonary bypass, and post-surgical ICU admission with multi-day hospitalization. Recognizing the potential advantages of a less invasive approach, the first attempts at percutaneous catheter-based dilation of stenotic pulmonary valves were performed in the 1950s. As the technique was refined and catheter and balloon technology have advanced, the results of balloon pulmonary valvuloplasty have improved and the approach has become the standard of care for treating pulmonary valve stenosis
Mouth rinsing solution, which is intended for preventing the formation of tartar, as well as the use of the active compound contained in the mouth rinsing solution. According to the invention, mineralization of the plaque, i.e. formation of tartar, can be eliminated by rinsing the tooth faces with a solution which contains a suitable compound that complexes calcium ions. Such a compound is, for example, such a sodium salt of ethylenediaminetetraacetic acid (EDTA) whose rinsing solution has a pH within the range of 5.5 to 9.0. The quantity of EDTA in the rinsing solution may be 1 to 20 %. The solution may also be made of a concentration of the said compound, or the said compound can be used as an additive in tooth paste.
Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The experimental stem (NT SL-PLUS) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron. The surface of the NT SL-PLUS stem was thereafter additionally treated chemically by short-acid etching with HF and mechanically by dry ice blasting in order to loosen and remove the residual alumina particles up to 96% without changing the existing surface microtopography.
PURPOSE:To provide the titled agent by adding a specific amino acid derivative to a penem-type or carbapenem-type antibiotic substance. CONSTITUTION:An antibiotic drug preparation having mitigated side effect (nephric toxicity) can be produced by compounding a penem-type or carbapenem- type antibiotic substance {e.g. the compound of formula I (X is -CH2-, -S-, etc.; R<1> is -CH2CH3, -CH2CH2F, etc.)} with the compound of formula II (R is acetyl or benzoyl; n is 0 or 1) (e.g. N-acetylphenylglycine, N-benzoylphenylglycine, N-acetylphenylalanine, N-benzoylphenylalanine, etc.). The weight ratio of the compound of formula II to the antibiotic substance is preferably 1/10-4. It is administered preferably by intravenous administration. Since the compound of formula II has low solubility in water in itself, an aqueous solution of a metallic compound such as NaOH is added to the dispersion of said compound to adjust the pH of the solution to 6-9 and effect the dissolution of the compound, and the solution is added with the antibiotic substance of formula I to obtain the objective pharmaceutical preparation.
While studies show that toys contain significant amounts of pathogenic microorganisms and may be effective in the spread of hospital-acquired infections, it appears that the literature and hospital practices on the disinfection of these toys are quite limited. Additionally, there is no routine practice to ensure toy hygiene in most health institutions. Therefore, in order to prevent the transfer of infectious agents through toys, policies and guidelines regarding toy cleaning methods and frequency should be established in hospitals. At the same time, families should be educated about the fact that toys can be a source of infection, and correct behavioral changes regarding toy hygiene should be created. When the literature was examined, it was determined that there were no routine hygiene practices regarding the cleaning of toys in children's clinics in Turkey. For this reason, the study will examine the effect of the toy hygiene education created by the researchers on the knowledge levels and practices of mothers and the surface cleaning of toys. It is thought that the results of the study will be a basis for creating clinical guidelines.
The invention is based on the traditional medical theory and the modern process technology and innovates a scheme for strengthening the body resistance and nourishing the lung, which has the advantages of safety, obvious effect, proper cost, simple and convenient taking and treatment based on syndrome differentiation. Bailingyangfu capsule for mild physique is the main product. The basic prescription is composed of eight herbal medicines such as radix stemonae, lucid ganoderma, platycodon grandiflorum, liquorice and the like. Has effects of invigorating qi, nourishing lung, dispelling pathogenic wind, relieving exterior syndrome, relieving cough, eliminating phlegm, relieving asthma, invigorating spleen, and removing dampness. Can be used for treating influenza, epidemic pneumopathy, cough, phlegm eliminating, asthma relieving, respiratory disorder, and spleen yang deficiency. The usage and dosage are as follows: 3-4 granules at a time, 3 times a day, in proper degree. And selecting a typing AB prescription aiming at different signs of cold and warm properties. For the auxiliary treatment of physical signs, dialectical treatment is required. The health care product is an auxiliary function, and an individual is the best doctor, follows a good life style, develops sanitary practice and obtains a healthy life. The Bailing has the effects of nourishing lung, serving sub-health people with lung syndrome, being high in safety, basically free of pain, injury and side effects, and being a health-care product for preventing and recuperating the patients.
In a body pack, preferably a face pack (1), small permanent magnets (3) having at least one north pole and one south pole are embedded in the binder composition (2). The permanent magnets (3) may have an irregular, disc-shaped, lentil-shaped or oval configuration and have a diameter of 2-10 mm. They are made of sintered or plastic-bound barium and/or strontium ferrite by compression, injection moulding or extrusion. The binder composition (2) has a consistency of high viscosity and contains cosmetic substances as well as completely or partially hardening substances, e.g. gypsum or clay. <IMAGE>
The table below indicates the volume of water to be added when constituting:

Add half the volume of water to the bottle and shake vigorously. Add the remainder of water to the bottle and shake.

Shake well before each use. Oversize bottle provides shake space. Keep tightly closed. Do not refrigerate. After mixing, store at 15° to 30°C (59° to 86°F) and use within 14 days.